MissionIR would like to highlight Cardium Therapeutics (http://www.missionir.com/market-research.html">NYSE: CXM), a health sciences and regenerative medicine company focused on the acquisition and strategic development of new and innovative bio-medical product opportunities and businesses with the potential to address significant unmet medical needs that have definable pathways to commercialization, partnering and other economic monetizations. Cardium's current medical opportunities portfolio, which is focused on health sciences and regenerative medicine, includes the Tissue Repair Company, Cardium Biologics, and the company's in-house MedPodium Health Sciences healthy lifestyle product platform.
In the company’s news yesterday,
Cardium Therapeutics announced that its To Go Brands® division has expanded its VitaRocks® kids vitamins product line and that retail distribution of the newly-designed products is being been expanded to include select Target stores.
The VitaRocks products are inspired by a popping pellet candy that is popular with kids and represents a next-generation, easy-use delivery platform for multivitamins and nutrients, dietary supplements, and potentially over-the-counter (OTC) medicines for children as well as adults. The Kids VitaRocks product line tastes great and delivers important vitamins and minerals needed by the body. Each packet provides 50% of Daily Value, so that children four and above can safely enjoy this nutritious treat twice a day. VitaRocks products include cherryBLAST, grapeGUSHER, the new blueRAZZ, as well as orangeBURST, providing 250 mg of Vitamin C. To Go Brands’ adult VitaRocks C delivers a powerful dose of 1000 mg of Vitamin C in every packet.
“Special formulations allow VitaRocks to melt cleanly in the mouth and deliver vitamins and nutrients while being fun and great tasting. Unlike many other products in this class, VitaRocks require no mixing with water and can be directly consumed. While the initial product line was designed for children, with the success of new adult multivitamin chews and gummies, consumers of all ages are increasingly seeking easy-to-use and great tasting nutritional products, and we believe that our VitaRocks platform aligns with this important and rapidly emerging trend. Because of our unique manufacturing process, we now have the flexibility to expand the product line into formulas that could include enzymes, electrolytes, amino acids, vitamins and minerals, as well as nutrients, and into other applications including OTC drugs,” stated Hanna Wagari, Cardium’s Vice President of Sales and Marketing.
Current VitaRocks products are available through retailers, including Whole Foods, Sprouts and Vitamin Shoppe. The new product line will be available at the beginning of April 2013 in select Target stores, as well as directly from the To Go Brands web-based store at www.togobrands.com.
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
To sign up for The MissionIR Report, please visit http://MissionIR.com
To connect with MissionIR via Facebook, please visit http://Facebook.com/MissionIR
To connect with MissionIR via Twitter, please visit http://Twitter.com/MissionIR
Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.